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1078–5The importance of angioplasty and stenting in the treatment of carotid artery disease cannot be underestimated. Successful
carotid stenting does not only depend of the operator’s skills and experience, but also an adequate selection of cerebral pro-
tection devices and carotid stents can help avoiding neurological complications. A broad spectrum of carotid devices is cur-
rently on the market and since all have their assets and downsides, it is virtually impossible to acclaim one specific device as
being the best. The individual characteristics of each specific protection system or stent may make it an attractive choice in
one circumstance, but render it a less desirable option in others situations. The applicability depends primarily on the ar-
terial anatomy and the specific details of the lesion being treated. But certainly, personal preferences and familiarity with
a specific device may legitimately influence the decision to choose one over another.
 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Carotid angioplasty and stenting (CAS) is increasingly
being performed for the treatment of severe carotid dis-
ease.1e5 Despite this trend, however, data from the two
largest and most recently published EVA-3S6 and
SPACE randomised trials7 failed to demonstrate non-
inferiority for CAS over CEA. Nevertheless, other pub-
lications suggest that with growing experience and the
development of dedicatedCAS technology, CAS can be
performed safely and efficiently.2,8
The number of dedicated CAS devices now com-
mercially available (stents and embolic protection de-
vices (EPD)) has increased considerably over the last
few years and has resulted in a bewildering array of
interventional options available to modern day CASe of a series of articles edited by Prof. A. Ross Naylor, Leices-
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884/000637+ 07 $34.00/0  2008 European Society for Vasculapractitioners. This variety in products makes individ-
ual treatment strategies difficult to generalise as no
single device possesses all of the optimal features to
treat all types of carotid plaques and patients.9
The aim of this paper is to review the principles of
device selection in contemporary CAS practice.Embolic Protection Devices
All commercial EPD systems can be classified under
three main groups, each with its own working princi-
ple (Fig. 1) and include; (1) distal occlusion balloon
protection (DOB), (2) distal filter protection (DF) and
(3) proximal occlusion devices (POD).Distal occlusion balloon protection
Distal occlusion devices (Table 1) evolved following
earlier developmental research by Theron10 in 1996.
A balloon is inflated in the internal carotid artery
(ICA) between the lesion and the brain so as tor Surgery. Published by Elsevier Ltd. All rights reserved.
Fig. 1. Working principle of A) distal occlusion balloons (DOB); B) distal filters (DF); and C) proximal occlusion devices
(POD).
638 M. Bosiers et al.temporarily prevent blood flow to the brain. Conse-
quently, athero-thrombotic debris cannot enter the ce-
rebral vasculature during the actual procedure. Prior
to deflation and restoration of flow, any debris is aspi-
rated and then flushed into either the external carotid
artery (ECA) or out of the body through a sheath in
the common carotid artery (CCA).
The main advantages of DOB protection devices
(compared to other EPDs) include their low crossing
profile and higher flexibility which facilitate overall
device delivery. However, complete occlusion of the
distal ICA may be potentially dangerous in patients
with insufficient cerebral collateralisation. Although
cerebral oxygenation can be maintained by intermit-
tent distal balloon deflation, this will inevitably com-
promise the quality of cerebral protection. Another
important disadvantage of complete ICA occlusion,
is that angiographic assessment of the target lesion
is not possible during balloon inflation within the
carotid stenosis.Distal filter device protection
Distal filter systems function like an umbrella which is
opened in the ICA between the target lesion and the
brain, in order to capture any debris during the CAS
procedure (Table 2). This debris is then removed atTable 1. Specifications of the commercially available distal occlu-
sion device
EPD Manufacturer Characteristic Lesion
crossing
profile (00)
PercuSurge
GuardWire
Medtronic
Vascular, Santa
Rosa, CA, USA
Manual
aspiration
0.036
Eur J Vasc Endovasc Surg Vol 35, June 2008following successful angioplasty and stent placement.
DFs can either be mounted on a guide wire, or with
their own dedicated delivery and retrieval system.
Most Interventionists consider the DF protection
principle as being, intuitively, the most attractive.
This is because there is maintenance of cerebral perfu-
sion during CAS and angiographic assessment of the
carotid lesion remains possible throughout all stages
of the procedure. DF thrombosis may occur during
the intervention, but its prevalence can be reduced
by ensuring full heparinisation. In the event of com-
plete DF blockage by embolic debris/thrombus,
a few rescue options are available. The debris/throm-
bus can be removed by DF aspiration, or the device
can be simply retrieved. After retrieval, the procedure
is either restarted with another protection device or
continued ‘unprotected’.Proximal occlusion devices
Proximal occlusion systems utilise two compliant bal-
loons which are sequentially inflated within the prox-
imal CCA and the ECA (Table 3). This double balloon
inflation creates either a ‘no-flow’ or a reversed-flow
pattern within the ICA, thus preventing debris embol-
ising to the brain. PODs are especially attractive as
complete cerebral protection is established before
crossing the lesion with guide wires or stent delivery
systems.
However, the procedural steps required to maneu-
ver the POD into the CCA and ECA are more labori-
ous compared with other EPDs. In addition, occlusion
of the ICA and CCA prevents blood flow to the brain
and (as with the DOB principle), patients with inade-
quate collateralisation will be vulnerable to cerebral
ischaemia. Intermittent deflation of the distal balloon
Table 2. Specifications of the commercially available distal filter devices
EPD Manufacturer Characteristic Pore size
(mm)
Lesion
crossing
profile (F)
Available filter
diameters (mm)
RX Accunet Abbott Vascular,
Redwood City,
CA, USA
Concentric 125 3.5e3.7 4.5, 5.5, 6.5, 7.5
Emboshield Pro Abbott Vascular,
Redwood City,
CA, USA
Eoncentric, bare
wire
120 2.8e3.2 Small¼ 2.5e4.8 mm
Large¼ 4.0e7.0 mm
FilterWire EZ Boston Scientific
Corp, Natick,
MA, USA
Eccentric 110 3.2 One size fits all
Angioguard Cordis, Miami
Lakes, FL, USA
Concentric 100 3.2e3.9 4, 5, 6, 7, 8
SpideRX ev3, Plymouth,
MN, USA
Eccentric Variable 3.2 3, 4, 5, 6, 7
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bral oxygenation, but will inevitably compromise the
efficacy of the protection.Recent EPD developments
The Twin-One device (Minvasys, Genevilliers, France)
evolved from the concept of temporary occlusion of
the distal internal carotid.10 The system combines an
angioplasty catheter pre-loaded with a DOB. The sys-
tem is designed to be used whilst performing dilation
after CAS has been performed as, according to its in-
ventors, this is the only phase of the procedure requir-
ing embolic protection. The latter concept is key to
understanding this device but it remains a topic of
considerable debate.
Another recently launched device is the FiberNet
(Lumen Biomedical, Plymouth, MN). This is the first
EPD to incorporate both a filter and an occlusion de-
vice in one system. The system consists of a 3-dimen-
sional expandable Polyethylene Terephthalate (PET)
fiber-based filter, which expands radially and is
mounted onto a 0.01400 wire and retrieval catheter.
The system can capture particles as small as 40Table 3. Specifications of the commercially available proximal
occlusion devices
EPD Manufacturer Characteristic Flow
pattern
Introducer
sheath
profile (F)
NPS W. L. Gore &
Associates,
Flagstaff,
AZ, USA
Separate CCA
and ECA
balloon
Reversed
flow
9F
Mo.Ma Invatec,
Roncadelle,
Italy
CCA and ECA
balloon
mounted
on same catheter
No flow 8Fmicrons without compromising flow. Upon comple-
tion of the CAS-procedure, the retrieval catheter is
advanced over the wire, and positioned just proximal
to the expanded filter. There are two focal suction
steps required for this filter. The first focal suction is
at the base of the filter to remove any material that
may be loosely bound to the filter. The second focal
suction is performed while the device is being re-
trieved. Contained and captured emboli are removed
by focal suction through the retrieval catheter and
also by their retention within the filter fibers.11EPD selection guidelines
Determining which EPD to use begins with assess-
ment of the intracerebral circulation. In the absence
of adequate cerebral collateralisation, it is probably
preferable to use a filter protection device as they
preserve blood flow to the brain. Although the
protective balloons in DOB and POD devices can
be temporarily deflated, it is our opinion that this
is a laborious technique which confers suboptimal
protection and an increased risk of procedural
embolisation and stroke.
Second, the access site needs to checked. Patients
presenting with tortuous iliac arteries or a type III aor-
tic arch require low-profile, flexible protection sys-
tems as the target carotid lesion is going to be
difficult to reach. As DOBs have crossing profiles
comparable to those of guidewires, they are always
steerable and flexible enough to pass through tortu-
ous vessels. Only small-profile, flexible DFs can nego-
tiate tortuous access vessels and (due to their large
calibre) POD devices are not to be recommended in
this situation.
The third key to device selection is good knowl-
edge of the anatomy and morphology of the carotidEur J Vasc Endovasc Surg Vol 35, June 2008
640 M. Bosiers et al.lesion. Severely stenosed and irregular lesions (in-
cluding near-occlusions) can be treated with most
EPD devices currently available. However, if a DF
protection device is preferred, it is important to select
low-profile, soft-tipped, flexible device as they are less
traumatic and less likely to cause complications. Sim-
ilarly, where a severely angulated ICA is anticipated,
PODs are probably the preferred option because it is
not necessary to cross the lesion. However, if a DOB
or DF system is preferred, ensure that it is either
highly steerable and flexible or, alternatively,
straighten the ICA using the ‘buddy-wire’ technique.
Should the ICA distal to the lesion be too tortuous
or there is too little space between the lesion site and
the cerebrum, distal protection systems cannot be
used because of a lack of space to ‘land’ the filter. In
this situation, PODs are the preferred option. Soft pla-
que lesions are probably more dangerous because
they have a greater tendency to embolize. Therefore,
undue trauma to the plaque surface must be mini-
mised. This is obviously not a problem when a POD
is used. However, caution must be exercised in this
situation should the Interventionist prefer to use
a DOB or DF device Here only low-profile, soft-
tipped, flexible devices should be selected.Evidence?
As only small differences in complication rates for the
varying protection devices are to be expected, hard
data from randomized controlled trials are currently
not (and probably never will be) forthcoming. In a re-
cent non-randomised comparison by El-Koussy et al,
they did find (using diffusion-weighted magneticTable 4. Specifications of the commercially self-expanding carotid s
Stent Manufacturer Desi
Carotid
Wallstent
Monorail
Boston Scientific Corp, Natick, MA, USA Wov
coba
Exponent RX Medtronic Vascular, Santa Rosa, CA USA Lase
nitin
NexStent
Monorail
Boston Scientific Corp, Natick, MA, USA Lase
nitin
Precise
Carotid Stent
Cordis, Miami Lakes, FL, USA Lase
nitin
Prote´ge´ RX ev3, Plymouth, MN, USA Lase
nitin
RX AccuLink
Carotid Stent
Abbott Vascular, Redwood City, CA Lase
nitin
long
X-Act Abbott Vascular, Redwood City, CA Lase
nitin
Crystallo
Ideale
Invatec, Roncadelle, Italy Lase
nitin
Eur J Vasc Endovasc Surg Vol 35, June 2008resonance imaging (DW-MRI)) a non-significant trend
toward fewer embolic events after CAS with POD ver-
sus DF protection. Both the total number of new le-
sions, as well as the volume of consistent (relevant)
new lesions, was non-significantly lower in the POD
group.12 These DW-MRI differences did not, however,
result in any difference in clinical outcome between
the two types of EPD. The latter observation was
also corroborated in a subanalysis of the Belgian Ital-
ian Carotid (BIC) Registry, which concluded that none
of the observed differences in 30-day event rates could
be attributed to EPD selection. Interestingly, many of
the observed differences were largely attributable to
the choice of stent used in conjunction with the EPD.13Carotid Stents
All commercially available self-expanding carotid stents
(Table 4) are composed of either nitinol (a nickele
titanium alloy) or stainless steel (a cobalt alloy). In
general, nitinol stents are constructed from a single la-
ser-cut. The only exception is the NexStent, which is
laser-cut from a nitinol sheet and coiled into a tube-
like form. The overlap area of the coiled structure
shrinks or grows as it is placed in larger or smaller
diameter vessels. Once deployed in the body, nitinol
stents rely on their thermal memory to achieve their
predefined shape. The only available stainless steel
stent is the Carotid Wallstent which is woven from
a single piece of cobalt alloy wire into a tubular struc-
ture. The stent is delivered in a retractable sheath and it
relies on a spring-like action to expand, once the sheath
is withdrawn.tents
gn Free cell area
(mm2)
Tapering
en closed-cell
lt-chromium tube
1.08 Self-tapering
r-cut open-cell
ol tube
6.51 Self-tapering
r-cut closed-cell
ol coiled sheet
4.70 Self-tapering
r-cut open-cell
ol tube
5.89 Self-tapering
r-cut open-cell
ol tube
10.71 Straight or
Shouldered tapered
r-cut open-cell
ol tube with
itudinal spines
11.48 Straight or
Conical tapered
r-cut closed-cell
ol tube
2.74 Straight or
Conical tapered
r-cut closed-cell
ol tube
Varying smaller
at mid portion,
larger at stent ends
Straight or
Conical tapered
641The Choice of Stent and Protection Device during Carotid AngioplastyScaffolding
Besides the material used to manufacture the stent,
many other design characteristics need to be consid-
ered when choosing the most appropriate stent for
the patient. While with carotid endarterectomy
(CEA) the complete plaque is removed from the
patient, following CAS it obviously remains in the
artery. The stent struts compress the dilated plaque
material and it is the actual mesh design of the stent
that has to then guarantee that no debris is dislodged
through the stent interstices. Accordingly, the stent’s
scaffolding properties (defined as the amount of sup-
port given to the vessel wall by the stent) are of major
importance in order to minimise the risk of embolic
complications.
The ‘free cell area’ is the best acceptedmethod to de-
scribe the scaffolding potential of carotid stents. From
the results of the BIC Registry,14 we learned that stents
with a smaller free cell area are better at containing pla-
que material behind the struts resulting in significant
differences in event rates compared to stents with large
free cell areas. These differences in outcomeweremore
pronounced among symptomatic patients.
Another often used classification for stent design is
the binary ‘‘open’’ and ‘‘closed’’ cell design one, in
which the differentiation is made by the number and
arrangement of bridge connectors. In closed cell stents
the adjacent ring segments are connected at every pos-
sible junction, while in open cell stents not all of the
junction points are interconnected. Fig. 2 shows that
an open-cell design might insufficiently scaffold a pla-
que in particularly tortuous arteries as the stent cells
open on the concave surface of any bend. This will
then predispose to protrusion of plaque after CAS
and an increased risk of embolisation to the brain.
‘‘Open’’ and ‘‘closed’’ cell design stents have been
evaluated in a number of early publications which
looked at the association between stent design and
outcome. Most concluded that patients treated with
closed-cell stents had significantly lower 30-day
stroke, death, and TIA event rates compared withFig. 2. Larger open-cell-designed stents insufficientlythose treated with open-cell-designed stents.16 This
has more recently been corroborated by a recent
subanalysis of the SPACE study data.7 However,
Wholey has suggested that this classification may be
an over-simplification giving the example that a closed
cell stent with a diameter of 1,000 mm is more likely to
be responsible for plaque prolapse and embolization
than an open cell of 500 mm.15 He concluded that
cell size and surface area coverage was more
important.Flexibility
The flexibility of a stent is defined as its ability to con-
form to vessel tortuosity during deployment. In terms
of flexibility, closed cell stents, both nitinol and stain-
less steel, do not perform as well as their open cell
counterparts. This is because in closed-cell stents the
adjacent ring segments are connected at every possi-
ble junction with flexible bridge connectors and only
a limited degree of flexion between adjacent rings is
possible. In the open-cell stent, not all junction points
are interconnected and this therefore allows much
more movement between adjacent ring segments
and a better conformability to tortuous anatomy. Ac-
cordingly, the flexion benefits of an open-cell design
are offset by less scaffolding uniformity, while the
scaffolding benefits of a closed-cell design are offset
by poorer flexion and conformability.15 If placed in
a tortuous carotid, closed-cell stents tend to alter the
vessel’s original curve. If it is not placed accurately,
the insertion of a less flexible closed-cell stent can
result in kinking of the carotid vessel just distal of
the implanted stent (Fig. 3).
One company (Invatec) has recently developed
a new stent design which incorporates varying sizes
of free cell area at the mid segment and both distal
edges of the stent (Crystallo Ideale). This should pro-
vide a compromise between achieving adequate scaf-
folding at the lesion site along with improved
flexibility at the stent edges.scaffold vulnerable lesions in tortuous anatomy.15
Eur J Vasc Endovasc Surg Vol 35, June 2008
Fig. 3. Stent selection for tortuous carotid lesions a) pre- and b) post-procedural angiography of CAS with open cell nitinol
stent (Precise) preserving original anatomy and c) pre- and d) post-procedural angiography of CAS with closed cell Cobalt
Chromium alloy stent (Carotid Wallstent) causing kinking of the artery distal of the lesion.
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Vessel wall adaptability describes the ability of a ca-
rotid stent to adjust itself to the tapered anatomy of
the region. Although it is typical for a nitinol tube-
like stent to convert to its predetermined shape
when exposed to body temperature, this is not always
achievable. In an attempt to better comply with the ca-
rotid anatomy, tapered stents have been developed.
These are characterized by a smaller stent diameter
at the distal end compared to the proximal end. There
are two types of tapered stents: the conical (Acculink,
X-Act) and the shouldered tapered stents (Prote´ge´). In
the first, there is a gradual decrease in diameter from
the proximal to the distal end, whereas in the second,
there is a short transition zone in the midsegment of
the stent. The coiled nitinol sheet configuration of
the NexStent allows the stent to adapt nicely to the
change in diameter. The stent overlap will differ
from the proximal to the distal stent end. The Precise
is claimed to be self-tapering because the different
rings interact independently with the vessel wall.
The woven mesh structure of stainless steel stents
allows the stent to adjust its diameter to the width
of the vessel lumen. This ensures optimal vessel
wall adaptability. Final implanted stent length de-
pends on the diameter of the lumen at the site of de-
ployment. If the lesion involves the CCA and the ICA,
the stent has to cover the carotid bifurcation com-
pletely. Flow disturbances in the ICA occur if the stent
is positioned in the bulb.17 In our experience, a signif-
icant mismatch in diameter between the ICA and the
CCA (e.g., 5 to 10 mm, respectively) occurs in only 10
to 15% of cases. In these cases, it is recommended that
a shouldered tapered stent such as the Prote´ge´ shouldEur J Vasc Endovasc Surg Vol 35, June 2008be selected. If appropriately sized and exactly posi-
tioned with its shoulders in the bulb, its diameter
adapts best to the original vessel diameter changes.
Stent selection guidelines
In light of the findings of the BIC Registry13,14 along
with awareness that once the EPD is removed, the
stent remains the only protection against brain-
embolization, plaque scaffolding should be the prime
determinant in selecting a carotid device. For exam-
ple, all symptomatic patients and those patients pre-
senting with a highly echogenic lesion (Grey Scale
Median> 25)18 should receive a stent with an as low
free cell area as possible.
If the selection of a stent with high scaffolding ca-
pacities might potentially compromise the mainte-
nance of the vessel’s initial anatomy (e.g. increase
the potential risk of causing a distal kink or significant
mismatch in proximal and distal diameter), the au-
thors would recommend performing a CEA. Selecting
a more flexible stent with less scaffolding in order to
achieve an optimal angiographic result after CAS,
could expose the patient to an increased risk of
post-procedural cerebral embolization.Conclusion
Following publication of the SPACE7 and EVA-3S6 re-
sults, it is our opinion that in addition to needing
more experienced Interventionists, there is still a need
for better designed CAS devices, especially stents.
This is because it remains our contention that it is the
stent’s scaffolding capacity that is of major importance
643The Choice of Stent and Protection Device during Carotid Angioplastyin preventing procedural events and the current gener-
ation of stents with good scaffolding properties are
compromised by insufficient flexibility. Future stent
design improvements should focus primarily on com-
bining improved scaffolding and flexibility.
Until that time, we would recommended that the
number of different EPDs and stents used in an indi-
vidual’s CAS practice should be relatively limited and
that he/she should become more intimately ac-
quainted with each of their ‘pros and cons’. Finally,
it is essential that in symptomatic patients and those
patients with vulnerable plaque, the choice of EPD
and stent must focus on atraumatic instalment.
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